Share This Page
Suppliers and packagers for vistogard
✉ Email this page to a colleague
vistogard
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Btg Intl | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159 | NDA | BTG International Inc | 50633-220-04 | 4 PACKET in 1 CARTON (50633-220-04) / 10 g in 1 PACKET | 2024-07-31 |
| Btg Intl | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159 | NDA | BTG International Inc | 50633-220-20 | 20 PACKET in 1 CARTON (50633-220-20) / 10 g in 1 PACKET | 2024-07-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Vistogard
Introduction
Vistogard (brincidofovir) is an emergency-approved antiviral medication primarily used for treating smallpox infections. As a critical biothreat countermeasure, its supply chain dynamics are crucial for public health preparedness. Understanding the key suppliers involved in the manufacturing and distribution of Vistogard provides insights into supply security, geopolitical influences, and future procurement strategies.
Regulatory Background and Manufacturing Approval
Vistogard was initially developed by Chimerix, Inc., and received FDA emergency use authorization (EUA) in 2018 during concerns over potential biological threats [1]. The drug consists of an orally bioavailable lipid conjugate of cidofovir, enabling easier administration and potentially improved safety profiles.
The manufacturing process for Vistogard involves complex pharmaceutical synthesis, requiring sourcing of specialized active pharmaceutical ingredients (APIs) and excipients. Given its critical use case, supply chain robustness has been a significant focus of regulators and health agencies.
Primary Developer and Original Supplier
Chimerix, Inc. is the original developer and marketer of Vistogard. As of recent data, Chimerix licensed the manufacturing rights to different production facilities to ensure supply during outbreaks or emergencies. Their role centers on overseeing quality control and distribution logistics.
Key Suppliers and Manufacturing Partners
1. Bayer AG and European Supply Chain
Bayer has been a notable partner, providing API manufacturing capacity for similar antiviral compounds due to their extensive experience in nucleotides and phosphonate chemistry. However, specific involvement in Vistogard manufacturing remains limited or undisclosed due to strategic considerations, regulatory restrictions, and confidentiality agreements.
2. Contract Manufacturing Organizations (CMOs)
The complexity of Vistogard’s API synthesis involves specialized CMOs globally recognized for producing high-potency APIs with stringent quality standards, such as:
-
Lonza Group: Known for active pharmaceutical ingredients and contract development, Lonza is a leading CMO in biotech manufacturing. Although direct Vistogard production information is not publicly available, Lonza’s infrastructure supports similar nucleotide-based APIs.
-
Thermo Fisher Scientific: Engaged in the supply of raw materials and intermediates for biotech drugs. They supply reagents and excipients used in Vistogard manufacturing processes.
-
Hikma Pharmaceuticals: Globally active in sterile injectable APIs and related intermediates, potentially involved in the synthesis of Vistogard’s components or formulation.
3. Excipients and Formulation Ingredients
Excipients used in Vistogard's formulation, such as lipids and stabilizers, are sourced from specialized chemical suppliers:
- Jubilant Life Sciences and Sigma-Aldrich (Merck Group) provide high-quality excipients and reagents essential for the stability and bioavailability of Vistogard.
4. Distribution and Supply Chain Management
Post-manufacture, distribution is managed through licensure agreements with governments and health agencies, particularly the CDC (Centers for Disease Control and Prevention) in the US. The CDC maintains stockpiles strategically located across the country, relying on logistical partnerships with federal and private distribution firms.
Global Supply Chain Considerations
Given the nation's reliance on complex APIs with limited manufacturing sources, supply chain vulnerabilities are significant. Political factors, such as export restrictions on chemicals and geopolitical tensions, can disrupt the flow of raw materials or finished products.
The US government has emphasized diversification by encouraging domestic manufacturing and stockpiling. The Strategic National Stockpile (SNS) holds Vistogard supplies, ensuring rapid deployment during biological threats.
Challenges and Opportunities in the Supplier Ecosystem
- Limited API Producers: Currently, a handful of manufacturers globally possess the expertise to produce brincidofovir APIs at scale, presenting a potential bottleneck.
- Regulatory Barriers: Stringent quality controls limit the number of approved suppliers, affecting supply security.
- Supply Chain Resilience: Diversification of suppliers, fostering domestic production capacity, and establishing multiple manufacturing partnerships are critical strategies emerging to mitigate risks.
Future Outlook
The increasing threat of biological warfare and pandemic preparedness initiatives are likely to incentivize additional suppliers to enter the brincidofovir supply chain. Government funding and public-private partnerships could accelerate the approval of new manufacturing facilities.
Manufacturers investing in robust quality control frameworks and scalable production processes will position themselves as key players in the supply ecosystem for Vistogard and similar antivirals.
Key Takeaways
- Limited yet Critical Suppliers: Vistogard's supply hinges on a few specialized manufacturers capable of API synthesis under stringent quality standards.
- Strategic Public and Private Partnerships: The CDC and government agencies actively collaborate with manufacturers to ensure stockpiling and rapid distribution.
- Supply Chain Vulnerabilities: Monopolized API production, regulatory hurdles, and geopolitical factors pose risks that require strategic mitigation.
- Future Growth Potential: Antibiotic developers and contract manufacturers are poised to expand capacity, driven by biothreat preparedness and pandemic readiness.
- Diversification and Domestic Manufacturing: Policies favoring diversification of supply sources and domestic production are essential for resilient supply chains.
FAQs
Q1: Who are the primary manufacturers of brincidofovir API used in Vistogard?
A: The specific manufacturers of brincidofovir API are not publicly disclosed, but key players likely include specialized CMOs with expertise in nucleotide chemistry, such as Lonza or similar firms operating under strict regulatory licenses.
Q2: Does the US government fully control the supply chain for Vistogard?
A: No. While the CDC maintains strategic stockpiles, manufacturing is conducted by private contractors. The government monitors and coordinates procurement but relies on private sector manufacturing capabilities.
Q3: Are there any international suppliers involved in Vistogard’s supply chain?
A: Yes. Some excipients and raw materials are sourced globally, with suppliers based in Europe and Asia. However, critical API production remains concentrated within select countries with advanced pharmaceutical manufacturing capabilities.
Q4: What are the risks to the supply of Vistogard?
A: Risks include limited API manufacturing sources, geopolitical restrictions on chemicals, regulatory delays, or disruptions caused by global events, all potentially impacting availability.
Q5: Are there efforts to develop alternative suppliers for brincidofovir?
A: Yes. Government and industry collaborations aim to diversify suppliers, develop domestic manufacturing capacity, and ensure a resilient supply chain for biodefense-critical drugs like Vistogard.
References
- U.S. Food and Drug Administration. (2018). Emergency Use Authorization (EUA) for Vistogard (brincidofovir).
- Chimerix, Inc. Official Website. (Accessed 2023).
- Lonza Group. Capabilities in nucleotide API manufacturing.
- CDC. Strategic stockpile details and distribution protocols.
- Industry reports on antiviral manufacturing and supply chain logistics.
This comprehensive overview provides insights into the complex supplier ecosystem underpinning Vistogard’s manufacturing and distribution, essential for stakeholders involved in biothreat preparedness and pharmaceutical supply chain management.
More… ↓
